Boston Scientific (BSX) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Q2 2026
EPS
$0.86
est $0.83
+3.9%
Revenue
$5.44B
est $5.37B
+1.4%
Five-quarter earnings beat streak intact as Cardiovascular segment growth of 8.3% powers $0.86 EPS and $5.44 billion revenue, with FARAPULSE pulsed field ablation system delivering clinical momentum and management launching a $500 million cost-reduction push.
BSX share price +1.42% since print
Mentioned: BSX